Tecarfarin is a novel oral vitamin K antagonist with a similar mechanism of action to warfarin, though it is metabolized differently.
Your search for ESKD returned 53 results
The systematic review and meta-analysis included a broad range of patients with and without chronic kidney disease.
Investigators report results from a systematic review and meta-analysis of data from 23 randomized controlled trials involving 15,144 patients with anemia of CKD.
Study findings do not support initiation of uric acid-lowering therapy to prevent CKD.
This study raises important questions about the choice between lactated Ringer and saline.
Study findings highlight an “unmet need” for newer therapies.
Affordability of SGLT2i may contribute to the low prescription rate in CKD.
In FIDELITY, investigators pooled data from more than 13,000 patients from the FIDELIO-DKD and FIGARO-DKD trials.
Hemoglobin levels lower, erythropoietin stimulating agent use higher, even for water lead levels below EPA threshold for regulatory action
A study found no significant increased risks for death or major adverse cardiac events among infected patients with established chronic kidney disease or end-stage kidney disease.